Top Markets
Coin of the day
TMS Co., Ltd. TMS Co., Ltd.

TMS Co., Ltd.

4891
Peringkat dalam Saham #27371
Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on... Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.
Harga Saham
$0.73072946
Kapitalisasi Pasar
$33.30M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-31.85%
Negara
JP
Perdagangan TMS Co., Ltd. (4891)

Kategori

Rasio P/B untuk TMS Co., Ltd. (4891)
Rasio P/B per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari TMS Co., Ltd., rasio P/B saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/B perusahaan adalah 0.
Riwayat rasio P/B untuk TMS Co., Ltd. dari 2026 hingga 2026
Rasio P/B pada akhir setiap tahun
Tahun Rasio P/B Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/B untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/B Perbedaan Rasio P/B Negara
6.3419 -
US
3.7087 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH